Polygenic Risk Scores Are Not Genetic Predispositions

Why It Matters

Mischaracterizing PRS as innate predispositions can mislead clinicians, patients, and policymakers, affecting how genetic risk information is communicated and applied in precision medicine.

Key Takeaways

• PRS are model‑derived risk estimates, not inherent genetic traits
• Risk estimates shift with reference population and environmental context
• High‑penetrance mutations differ: they have known biological mechanisms
• Essentialist language may distort public and clinical perception of genetics

Pulse Analysis

Polygenic risk scores have surged into the spotlight of precision medicine, promising to quantify an individual’s susceptibility to complex diseases such as diabetes, heart disease, and schizophrenia. Yet, unlike single‑gene mutations with well‑defined pathways, PRS are constructed by summing thousands of variants weighted by their statistical association in large genome‑wide studies. This statistical nature means the scores are highly sensitive to the ancestry of the discovery cohort and the environmental variables embedded in the training data. When a PRS derived from European‑centric datasets is applied to an Asian or African individual, predictive performance can drop dramatically, underscoring the need for diverse reference panels before the scores can be trusted in clinical settings.

The tendency to label PRS as "genetic predispositions" taps into a deep‑seated essentialist intuition that genes are fixed determinants of fate. Such framing, however, obscures the probabilistic and context‑dependent reality of these scores. By presenting risk as an intrinsic property, media narratives and even some scientific papers risk overstating certainty, potentially prompting premature clinical decisions or unwarranted anxiety among patients. Clear communication that emphasizes the conditional and model‑based nature of PRS can help align expectations with the current state of evidence, fostering more responsible integration of genomics into health care.

From a policy perspective, the distinction matters for regulation, insurance underwriting, and ethical oversight. If PRS are treated as definitive predispositions, regulators may feel pressured to impose stringent oversight akin to that for pathogenic variants, while insurers might consider them grounds for differential pricing. Recognizing PRS as statistical tools rather than immutable traits supports a balanced approach: encouraging continued research, promoting equitable data collection across populations, and developing guidelines that reflect their probabilistic character. This nuanced view can accelerate the responsible adoption of polygenic risk information while safeguarding against misinterpretation.